Cancer

Receiving radiation for prostate cancer increases the risk of other cancers very slightly, Stanford Medicine researchers find, allowing providers to better inform patients weighing treatment options.

Stanford Medicine researchers have created a molecule that blocks an enzyme thought to be instrumental in causing colon cancer relapse or chemotherapy resistance.

The funding, from Cancer Grand Challenges, will help the researchers address difficult problems in cancer prevention, treatment-resistant cancers and therapies for pediatric solid tumors.

Researchers found that damage to the brain’s white matter after COVID-19 resembles that seen after cancer chemotherapy, raising hope for treatments to help both conditions.

Native Hawaiians and other Pacific Islanders experience poorer breast cancer survival outcomes that are hidden when their data is included in Asian populations, Stanford researcher says.

Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug. The modified cells are safer, more potent and more active against solid tumors in mice.

Hematologist Jason Gotlib wanted more effective treatments for patients with systemic mastocytosis. His research has led to the approval of two new treatments by the Food and Drug Administration.

The structure of a critical cellular-signaling molecule has finally been discovered by Stanford researchers. The finding may lead to new therapies.

Tuberculosis lesions in the lungs have high levels of proteins that suppress the immune system. Cancer drugs that target these proteins could be used to fight the bacterial infection.

Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before them, Stanford researchers say.

Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered.